Review of the proliferation inhibitor everolimus (Q33345496)

26 July 2017

1 reference

title

Review of the proliferation inhibitor everolimus (English)

1 reference

26 July 2017

Björn Nashan

1

1 reference

PubMed ID

12457444

26 July 2017

language of work or name

English

0 references

publication date

1 December 2002

1 reference

Expert Opinion on Investigational Drugs

26 July 2017

1 reference

26 July 2017

11

1 reference

26 July 2017

12

1 reference

26 July 2017

1845-1857

1 reference

Chemical modification of rapamycin: the discovery of SDZ RAD.

26 July 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Chronic allograft nephropathy: An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Current thinking on chronic renal allograft rejection: issues, concerns, and recommendations from a 1997 roundtable discussion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Increased impact of acute rejection on chronic allograft failure in recent era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Successful treatment of acute, ongoing rat lung allograft rejection with the novel immunosuppressant SDZ-RAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen usi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Prevention of small airway obliteration in a swine heterotopic lung allograft model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

RAD in de novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.12.1845

10.1517/13543784.11.12.1845

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference

PubMed ID

12457444